secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001104659-26-010633
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q4 net loss $0.29/shr; SOL-1 data readout at Macula Society Feb 25-28
--------------------------------------------------------------------------------

- Q4 2025 net revenue $13.3M, down 22.4% YoY; full year $52.0M, down 18.5%.
- Net loss Q4 $64.7M ($0.29/shr), full year $265.9M ($1.42/shr); R&D spend rose to $50.8M.
- SOL-1 Phase 3 wet AMD superiority data to be presented at Macula Society meeting Feb 25-28, 2026.
- Plans to submit NDA for AXPAXLI in wet AMD based on SOL-1, pending positive results and FDA interactions.
- Cash $737.1M as of Dec 31, 2025; raised $475M in Sep 2025 equity offering; runway into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/0001104659-26-010633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/tm265061d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-010633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer